 |
|
Successful Implementation Of Pilot Study For Hiv Antiretroviral Therapy In Uganda (p 34)
July 03, 2002Authors of a study in this week's issue of THE LANCET report on the successful implementation of a UNAIDS/Uganda Health Ministry initiative to provide antiretroviral treatment to people with HIV/AIDS in Uganda.
Little is known about how to implement complex HIV-1 treatment programmes in resource-limited countries. Paul Weidle from the Centers for Disease Control and Prevention, USA, and colleagues from Uganda assessed the UNAIDS/Uganda Ministry of Health HIV Drug Access Initiative-one of the first pilot antiretroviral programmes in Africa-in which patients paid for their medications at negotiated reduced prices.
912 patients were treated at five Ugandan centres; the investigators assessed the care of 476 patients at three centres, of whom 399 started antiretroviral therapy. Most patients accessed care at an advanced stage of HIV disease (median CD4 cell count 73 cells/mm3; viral load 193 817 copies/ml). Half the patients (51%) received highly active antiretroviral therapy (HAART), just under half (47%) received dual nucleoside reverse transcriptase inhibitors (2NRTIs), and 2% received a single NRTI.
An effective system for medical care and drug distribution was implemented resulting in an uninterrupted supply of drugs that supported sustainable management of patients. Patients returning for visits reported good adherence to treatment and achieved beneficial virologic and immunologic responses similar to those seen in more developed settings. The percentage of patients surviving and staying on therapy at six months was 63% and at one-year was 49%. Those with most advanced disease, a CD4 white blood cell count of less than 50 per microlitre of blood, were nearly three times as likely to die.
Paul Weidle comments: "This pilot programme showed that AIDS patients in a developing country can be managed successfully with antiretroviral therapy. Promoting access to therapy earlier in the course of the patient's disease, increasing the use of HAART, and finding solutions to reasons for discontinuing therapy would further improve patients' outcome in this setting. Although limited in scope, this pilot initiative provides valuable information for expanding access to antiretroviral therapy throughout Africa, despite the many challenges that will be faced along the way. In this way, effective AIDS care can reach more of those in need."
Lancet
HIV Current Events and HIV News RSSStudy sheds light on causes of HIV dementia
A new study led by researchers at Albert Einstein College of Medicine of Yeshiva University has clarified how two major variants of HIV differ in their ability to cause neurologic complications.
New HIV film tackles stigma faced by teachers in Africa
Addressing the discrimination against HIV-positive teachers in Africa is a key aim of a new documentary and accompanying book being launched in Senegal today by the Partnership for Child Development based at Imperial College London.
Selenium may slow march of AIDS
Increasing the production of naturally occurring proteins that contain selenium in human blood cells slows down multiplication of the AIDS virus, according to biochemists.
ACP recommends routine HIV screening for all patients
On World AIDS Day, the American College of Physicians (ACP) is giving doctors a call-to-action to routinely encourage HIV screening to all of their patients older than 13 years. This new practice guideline appears on the Annals of Internal Medicine Web site at www.annals.org.
Study of ancient and modern plagues finds common features
In 430 B.C., a new and deadly disease-its cause remains a mystery-swept into Athens. The walled Greek city-state was teeming with citizens, soldiers and refugees of the war then raging between Athens and Sparta.
Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models.
UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs
Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents.
More at-risk teens and young adults engaging in anal intercourse
A new study by researchers at the Bradley Hasbro Children's Research Center suggests that the incidence of heterosexual anal sex is increasing among teens and young adults - particularly those who have recently had unprotected vaginal sex.
Landmark study defines benefits of early HIV testing and treatment for infected infants
Testing very young babies for HIV and giving antiretroviral therapy (ART) immediately to those found infected with the virus dramatically prevents illness and death, according to a report in the New England Journal of Medicine.
Stopping germs from ganging up on humans
Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson.
More HIV Current Events and HIV News Articles
 | The First Year: HIV: An Essential Guide for the Newly Diagnosed (First Year, The) by Brett Grodeck This supportive resource explores the next generation of HIV/AIDS drugs and also includes new research on HIV and crystal meth, as well as new insights for the hardest hit population — African... |
 | The Naked Truth: Young, Beautiful, and (HIV) Positive by Marvelyn Brown, Courtney E. Martin The surprisingly hopeful story of how a straight, nonpromiscuous, everyday girl contracted HIV and how she manages to stay upbeat, inspired, and more positive about life than ever before At nineteen years of age, Marvelyn Brown was lying in a stark white hospital bed at Tennessee Christian Medical Center, feeling hopeless. A former top track and basketball athlete, she was in the best shape of... |
 | HIV/AIDS: A Very Short Introduction (Very Short Introductions) by Alan Whiteside HIV/AIDS is without doubt the worst epidemic to hit humankind since the Black Death. As of 2004 an estimated 40 million people were living with the disease, and about 20 million had died. Despite rapid scientific advances there is still no cure and the drugs are expensive and toxic. In the developing world, especially in parts of Africa, life expectancy has plummeted to below 35 years, causing... |
 | 100 Questions and Answers About HIV and AIDS by Joel Gallant |
 | The Guide to Living with HIV Infection: Developed at the Johns Hopkins AIDS Clinic (A Johns Hopkins Press Health Book) by John G. Bartlett, Ann K. Finkbeiner The Guide to Living with HIV Infection is the most complete source of medical, emotional, social, and practical advice available for those infected with HIV and their loved ones. Developed at the Johns Hopkins AIDS Clinic, the guide provides essential information for making decisions about treatment and testing in a world transformed by new research and pharmacotherapy.In this thoroughly updated... |
| Medical Management Of HIV Infection 2007 by John G. Bartlett, Joel E., M.D. Gallant | |
 | Healing HIV: How To Rebuild Your Immune System by Jon D., M.D. Kaiser, Jon D. Kaiser |
 | The Cure For HIV / AIDS by Hulda, R. Clark Including new research and findings showing what the true causes of HIV & AIDS are and lead directly to their cure! 53 CURED Cases The First Year Cure, not treatment, is the subject of this book. In 1991 Dr Clark discovered the source of HIV. Once the source became clear the cure became obvious. but would it work? After curing 53 cases in a row, all who used this method, Dr Clark could wait no... |
 | Living Well with HIV & AIDS by Allen Gifford, Kate Lorig, Diana Laurent, Virginia Gonzalez Based on the current care guidelines from the CDC and elsewhere, this book addresses the current emphasis on managing the side effects of HIV/AIDS such as lypodystrophy, redistribution of body fat, cardiac risks, and vulnerability to other ailments. Combining the latest medical advice with the ideas of hundreds of people living with HIV/AIDS, the book is particularly helpful for friends, family... |
 | HIV and the Pathogenesis of AIDS, 3rd Edition by Jay A. Levy The new edition of HIV and the Pathogenesis of AIDS provides a state-of-the-art review of the current research, explains the history of the disease, and examines how scientists, clinicians, and public health workers have responded to the challenges presented by HIV/AIDS in the 25 years since its recognition. Many exciting developments in the field have deepened scientific understanding of... |
| © 2008 BrightSurf.com |